V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210002702 | 210006199 | 1.64 | 92.45 | null | null | 2016-09-22 | null | 02 | null | FEC + DOCETAXEL | 101459210 |
| 210002706 | 210006200 | 1.67 | 83.5 | null | 2017-03-24 | 2017-04-08 | Cyclophosphamide + Docetaxel | 02 | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 101742395 |
| 210002709 | 210006202 | null | null | null | 2020-09-26 | 2020-10-11 | Paclitaxel+Trastuzumab wkly Maint | null | null | PACLITAXEL + TRASTUZUMAB | 100935404 |
| 210002717 | 210006209 | 1.73 | 74.4 | null | 2019-02-18 | 2019-03-14 | FEC 60 or 75 | null | null | FEC | 101177175 |
| 210002718 | 210006210 | 1.78 | 79.6 | Palliative (P) | 2016-08-24 | 2016-09-11 | EC | 02 | N | EC | 100031869 |
| 210002720 | 210006212 | null | null | null | 2017-11-05 | 2018-02-04 | EC | null | null | EC | 101736344 |
| 210002725 | 210006215 | 0 | 66 | Adjuvant (A) | null | 2018-10-14 | null | null | N | ATEZOLIZUMAB + NAB-PACLITAXEL | 100897893 |
| 210002726 | 210006216 | null | null | null | 2016-12-18 | 2016-12-18 | FEC + DOCETAXEL | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100496962 |
| 210002727 | 210006217 | null | null | null | 2019-08-13 | 2019-08-22 | FEC + DOCETAXEL | null | null | EC | 101352147 |
| 210002729 | 210006219 | 1.5 | 83 | Palliative (P) | 2019-10-20 | 2019-10-30 | null | null | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100087721 |
| 210002730 | 210006220 | 1.54 | 89.3 | Neo-adjuvant (N) | 2018-12-03 | 2018-12-16 | null | N | N | CISPLATIN + GEMCITABINE | 101276214 |
| 210002733 | 210006222 | 1.61 | 64.4 | Palliative (P) | 2020-09-27 | 2020-10-08 | FEC + DOCETAXEL | N | N | FEC + DOCETAXEL | 101216086 |
| 210002734 | 210006223 | 1.7 | 82.3 | Neo-adjuvant (N) | null | 2018-09-13 | Paclitaxel+Trastuzumab wkly Maint | N | N | PACLITAXEL + TRASTUZUMAB | 101390420 |
| 210002737 | 210006225 | 1.57 | 69.5 | null | null | 2018-04-15 | FEC 100 | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100852551 |
| 210002740 | 210006227 | 1.74 | 67.9 | Adjuvant (A) | 2019-09-24 | 2019-10-10 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101734692 |
| 210002745 | 210006231 | 1.61 | 84.4 | Neo-adjuvant (N) | 2019-06-25 | 2019-07-02 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | null | CYCLOPHOSPHAMIDE + DOCETAXEL | 101607927 |
| 210002746 | 210006232 | 1.67 | 51 | null | 2017-01-28 | 2017-02-19 | FEC 100 | null | null | FEC | 101764552 |
| 210002748 | 210006233 | 1.6 | 88.3 | Palliative (P) | null | 2016-04-13 | EC + DOCETAXEL | null | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100649391 |
| 210002750 | 210006234 | 1.65 | 68 | Neo-adjuvant (N) | 2016-05-02 | 2016-05-19 | null | null | N | CARBOPLATIN + DOCETAXEL | 101359563 |
| 210002753 | 210006236 | null | null | null | 2016-07-28 | 2016-08-07 | Trial Unspecified | null | null | LETROZOLE + PALBOCICLIB | 101849442 |
| 210002754 | 210006237 | 1.58 | null | Neo-adjuvant (N) | 2016-04-15 | 2016-04-23 | EC | null | N | EC | 101343732 |
| 210002757 | 210006240 | null | null | null | 2016-02-27 | 2016-06-02 | null | null | null | CYCLOPHOSPHAMIDE + DOCETAXEL | 101755554 |
| 210002760 | 210006243 | 1.61 | 57.7 | Palliative (P) | 2018-07-19 | 2018-08-03 | FEC 60 or 75 | N | N | FEC | 101454782 |
| 210002761 | 210006244 | null | null | null | 2016-08-31 | 2016-09-09 | Paclitaxel+Trastuzumab wkly Maint | 02 | null | PACLITAXEL + TRASTUZUMAB | 100837925 |
| 210002763 | 210006246 | null | null | null | null | 2014-02-01 | FEC 60 or 75 | N | null | FEC | 100078713 |
| 210002764 | 210006247 | 1.57 | 69.8 | Palliative (P) | null | 2019-01-08 | FEC + DOCETAXEL | 02 | N | FEC + DOCETAXEL | 100270661 |
| 210002766 | 210006249 | null | 79.4 | null | 2019-02-25 | 2019-03-13 | FEC 60 or 75 | null | null | FEC | 100981886 |
| 210002776 | 210006258 | 1.47 | 94.2 | Palliative (P) | 2018-08-04 | 2018-10-16 | EC | null | N | EC | 100690882 |
| 210002779 | 210006261 | null | null | null | 2018-10-07 | 2019-01-03 | Palbociclib | N | null | PERTUZUMAB | 100559144 |
| 210002781 | 210006262 | 0 | 77.7 | Neo-adjuvant (N) | 2018-09-08 | 2018-10-02 | FEC + DOCETAXEL | 01 | N | FEC + DOCETAXEL | 100515355 |
| 210002784 | 210006265 | null | null | null | 2018-09-15 | 2018-09-15 | null | 02 | null | PERTUZUMAB | 101651624 |
| 210002785 | 210006266 | null | null | null | 2017-02-18 | 2017-02-18 | FEC 100 | null | null | FEC | 101711722 |
| 210002787 | 210006268 | 1.74 | 63.6 | Neo-adjuvant (N) | null | 2018-06-08 | FEC 60 OR 75 + DOCETAXEL | N | N | FEC + DOCETAXEL | 100511243 |
| 210002788 | 210006269 | null | null | Adjuvant (A) | 2017-01-21 | 2017-01-28 | Paclitaxel+Trastuzumab wkly Maint | 01 | N | PACLITAXEL + TRASTUZUMAB | 100834408 |
| 210002794 | 210006274 | 1.64 | 72.2 | Neo-adjuvant (N) | null | 2021-03-16 | ROSCO Trial | N | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100726234 |
| 210002795 | 210006275 | null | null | null | 2019-11-12 | 2019-12-04 | null | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100587603 |
| 210002799 | 210006279 | 1.61 | 80.45 | Curative (C) | 2018-12-19 | 2018-12-25 | ATEZOLIZUMAB + NAB PACLITAXEL | 01 | N | CAPECITABINE | 100215459 |
| 210002800 | 210006280 | null | null | null | 2018-02-04 | 2018-09-07 | Paclitaxel+Trastuzumab wkly Maint | null | null | PACLITAXEL + TRASTUZUMAB | 101314266 |
| 210002801 | 210006281 | 1.7 | 99 | Neo-adjuvant (N) | 2017-06-18 | 2017-06-23 | ROSCO Trial | null | N | CARBOPLATIN | 101390908 |
| 210002811 | 210006290 | 1.56 | 71.7 | Palliative (P) | 2018-11-25 | 2018-12-29 | null | N | N | EPIRUBICIN | 101738903 |
| 210002812 | 210006291 | 1.64 | 110.3 | null | null | 2017-12-07 | FEC 60 OR 75 + DOCETAXEL | N | null | FEC + DOCETAXEL | 101372776 |
| 210002815 | 210006293 | 1.6 | 62.5 | Neo-adjuvant (N) | 2018-12-04 | 2018-12-25 | FEC + DOCETAXEL | 02 | null | FEC + DOCETAXEL | 100882474 |
| 210002816 | 210006294 | null | null | null | 2018-12-08 | 2018-12-21 | FEC 100 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101568694 |
| 210002819 | 210006297 | 1.66 | null | Neo-adjuvant (N) | 2019-05-25 | 2019-05-25 | EC | 02 | N | EC | 100297554 |
| 210002822 | 210006300 | 1.6 | 56.8 | Adjuvant (A) | 2017-02-03 | 2017-04-26 | null | 02 | N | ATEZOLIZUMAB + NAB-PACLITAXEL | 100138316 |
| 210002827 | 210006303 | 1.71 | 71 | Palliative (P) | 2017-02-18 | 2017-02-18 | FEC 100 | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100992096 |
| 210002828 | 210006304 | null | 58.05 | null | null | 2017-06-27 | null | null | null | CARBOPLATIN + GEMCITABINE | 101782261 |
| 210002830 | 210006306 | 1.63 | 73 | Palliative (P) | 2017-10-20 | 2017-10-27 | EC | 02 | N | EC | 100861905 |
| 210002831 | 210006307 | 1.66 | 75.55 | null | 2017-03-22 | 2017-04-03 | null | null | null | CAPECITABINE | 101667257 |
| 210002836 | 210006310 | 1.65 | 67.7 | null | 2017-04-07 | 2017-07-05 | FEC 100 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100919568 |